Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients

J Neuroimmunol. 2003 Jun;139(1-2):84-92. doi: 10.1016/s0165-5728(03)00135-8.

Abstract

Purpose: To investigate the effects of interferon-beta-1a (IFN-beta-1a) on the trafficking of cell populations in peripheral blood cells of multiple sclerosis (MS) patients.

Methods: In this open-label pharmacodynamic study, peripheral blood was obtained from 10 relapsing-remitting (RR) MS patients just prior to and at 1, 2, 4, 8, 24, 48, 120, and 168 h after intramuscular injection of 30-microg IFN-beta-1a. Timed samples were also obtained from five controls at 0, 8, 24, 48 and 168 h. The blood cells were analyzed using four-color flow cytometry with antibody conjugates directed against cell surface proteins specific for T cells, B cells, NK cells, and the activation marker, CD69.

Results: IFN-beta-1a treatment resulted in selective, time-dependent effects on many cell populations in peripheral blood. The trafficking of T-helper and T-suppressor/cytotoxic subsets of T cells were qualitatively different. The most prominent effects were on the trafficking of natural killer cells, the levels of which decreased to 23.5% of pretreatment values at 8 h after treatment. The levels of CD69-positive NK cells increased to a peak value of 606% of pretreatment levels at the 24-h time point. In untreated controls, these characteristic trafficking effects were not observed. There was inter-patient heterogeneity in the levels of activated NK cells at the 6-month time point that may potentially be relevant for individualizing IFN-beta therapy.

Conclusions: IFN-beta treatment can induce specific, selective, and time-dependent trafficking of cells and its effects on different subsets of a given cell type are not qualitatively similar. The dynamics indicate that the activation of NK cells by IFN-beta is possibly dependent on the trafficking of NK cells. The activated NK cell levels after prolonged therapy may potentially provide a surrogate marker for IFN-beta exposure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Cell Adhesion Molecules / drug effects
  • Cell Adhesion Molecules / immunology
  • Cell Adhesion Molecules / metabolism
  • Chemotaxis, Leukocyte / drug effects*
  • Chemotaxis, Leukocyte / immunology
  • Female
  • Flow Cytometry
  • Granulocytes / drug effects
  • Granulocytes / immunology
  • Humans
  • Immunity, Cellular / drug effects*
  • Immunity, Cellular / immunology
  • Interferon-beta / pharmacology*
  • Interferon-beta / therapeutic use
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology
  • Leukocytes / drug effects*
  • Leukocytes / immunology
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Lymphocytes / drug effects
  • Lymphocytes / immunology
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*
  • Reaction Time / drug effects
  • Reaction Time / immunology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Adjuvants, Immunologic
  • Cell Adhesion Molecules
  • Interferon-beta